Literature DB >> 17105420

Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement?

Anna Maria Berghella1, Ida Contasta, Patrizia Pellegrini, Tiziana Del Beato, Domenico Adorno.   

Abstract

This paper focuses on our data on colon cancer patients. Our overall results lead us to believe that the suppressive effect of specific cytokines in colon cancer patients alters the functionality of TH1 and TH2 subsets of CD4+ T-cells, with an expansion of TH2 cells and a malfunctioning of TH1 cells. This immunological disregulation appears to increase with stage progression, suggesting a direct role in the mechanisms that allow the tumour to locate and expand within the host. It is also clear that in order to identify disease markers and generate an in vivo immune response that corrects the imbalance between TH1 and TH2 cells, we need to understand how tumour mechanisms cause this imbalance to begin with.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105420     DOI: 10.1089/cbr.2006.21.468

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  3 in total

Review 1.  Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.

Authors:  Aaron J Schetter; Niels H H Heegaard; Curtis C Harris
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

2.  Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.

Authors:  Aaron J Schetter; Giang Huong Nguyen; Elise D Bowman; Ewy A Mathé; Siu Tsan Yuen; Jason E Hawkes; Carlo M Croce; Suet Yi Leung; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

3.  The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers.

Authors:  Jiansheng Wang; Kaiyu Xu; Jing Wu; Chenghua Luo; Yuchen Li; Xuebin Wu; Hong Gao; Guosheng Feng; Bao-Zhu Yuan
Journal:  BMC Cancer       Date:  2012-09-21       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.